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1. Introduction 
The chapter highlights the current drug delivery strategies and phenomenon involved in the 
design of neural architectures employed for neuropharmaceutical applications attempting to 
replicate the nervous tissues. We seek to give an overview of the current drug delivery 
approaches such as degradable/diffusion-based delivery systems, affinity-based delivery 
systems, and immobilized drug delivery systems used to generate bioactive-release from 
scaffolds for neural tissue engineering applications. We talk about the combinatorial approach 
being employed in recent years in the form of “new generation of multifunctional 
biomaterials” which are - able to mimic the molecular regulatory characteristics by providing a 
three-dimensional architecture representing the native extracellular matrix and also able to 
sequester and deliver biomolecular moieties in highly specific manner. A special focus will be 
given to the micro- and nano-structured scaffolds which have been proved to be effective in 
axonal repairing, in guiding functional neurogenesis and in controlling stem cell 
differentiation. Emphasis will be given to the processing requirements for synthetic and 
natural polymers and biomaterials for producing potential scaffold materials as well as to the 
templating of the target drugs with their benefits and drawbacks. A detailed discussion will be 
provided for certain specialised and recently developed architectures in the form of injectable 
matrices, electrospun nanofibers, and hydrogels. Injectable scaffolds provide a very unique 
advantage of being a non-invasive approach for neural tissue engineering as further damage 
to the soft neural tissue due to surgery can be prevented. Current injectables in tissue 
engineering consists of gelation methods based on in situ chemical polymerization and 
crosslinking, photo-initiated polymerization and crosslinking, thermogelling injectable 
systems, ionic crosslinking, and self-assembling. Injectable scaffolds also provide opportunities 
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for drug delivery in the form of composite materials with embedded micro- and nanoparticles. 
Additionally, the easy customization of the injectable architectures by modification of 
solidification, porosity, biofunctionalization, mechanical properties, and biodegradation is an 
added attribute. The electrospinning process, on the other hand can be used to engineer neural 
architectures having micro to nanoscale topographical cues as well as micromeritic properties 
similar to the extracellular matrix. Enhanced cell attachment, drug loading, and mass transfer 
properties can be easily obtained by changing the surface-to-volume ratio and by controlling 
the bulk mechanical properties of electrospun scaffolds where the fibers can also be oriented or 
arranged randomly, to regulate the biological response to the scaffold. Drugs ranging from 
anti-inflammatory and antibiotic agents to growth factors, proteins, DNA, and RNA, and even 
living cells can be incorporated into electrospun scaffolds. Interventionally, the current tissue 
engineering and therapeutic approaches pertaining to neural injuries will be analysed and 
critiqued in detail with respect to various strategies, perspectives, challenges and expanding 
opportunities. Considerable efforts have been carried out to enhance the properties of tissue 
engineering architectures via surface engineering and surface functionalization for providing 
an extracellular matrix mimicking environment for better cell adhesion and tissue in-growth. 
These modifications can be carried out through plasma treatment, wet chemical method, 
surface graft polymerization, and co-fabrication of surface active agents and polymers. These 
modifications can further be designed and customised to release bioactive molecules, such as 
growth factors, DNA, or drugs, in a sustained manner to facilitate tissue regeneration (Figure 
1) [1]. Target molecules are usually loaded on the surface of scaffolds by physical adsorption, 
nanoparticles assembly on the surface, layer-by-layer multilayer assembly, and chemical 
immobilization. Tissue engineering scaffolds can deliver bioactives via certain signals such as 
interspersed signals, immobilized signals and signal delivery from cells and hence act as 
specialised and desired controlled release matrices. 
Material choices for the fabrication of neural architectures will be elucidated among, but not 
limited to, synthetic polymers such as poly(lactic acid), poly(glycolic acid) and co-polymers; 
poly(lactic acid-co-ethylene glycol); synthetic polyesters (PLA, PLGA) and collagen blends; 
aliphatic/aromatic degradable polyesters; polyfumarates; poly(ethylene terephtalate)–
poly(butylene terephtalate); polyhydroxyalkanoates; poly(glycerol sebacate); hydroxyl 
group containing polymers; amine group containing polymers; poly(amido-amines)s; N-
succinimidyl tartarate monoamine–poly(ethylene glycol)-block poly(D,L-lactic acid); 
poly(depsipeptide-co-lactide); poly(urethane)s; pluronic F-127 (PEO–PPO–PEO); tyrosine-
derived polycarbonates; polyorthoesters; polyphosphazenes; polyanhydrides; polypyrrole; 
and poly ether ester amides and natural polymers such as alginates, chitosan, hyaluronans, 
and carageenans as well as self-assembling peptides. 
Specific and representing examples cited, but not limited to, are as follows: Incorporation of 
protein-eluting microspheres (poly(lactide-co-glycolide) (PLGA 50/50)) into biodegradable 
nerve guidance channels (chitin tubes) for controlled release of growth factor; sodium 
tripolyphosphate cross-linked chitosan microspheres for controlled release of bioactive nerve 
growth factor; multifunctional, multichannel bridges that deliver neurotrophin encoding 
lentivirus (encoding the neurotrophic factors NT-3 or BDNF) for regeneration following spinal 
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cord injury (combining gene delivery with biomaterials); poly(2-hydroxyethyl methacrylate-
co-methyl methacrylate) nerve guidance channels as nerve growth factor delivery vehicles; 
regrowth of axons in lesioned adult rat spinal cord: promotion by implants of cultured 
Schwann cells; and sustained release of dexamethasone from hydrophilic alginate hydrogel 
matrices using PLGA nanoparticles for neural drug delivery. 
 
Figure 1. Surface engineered and growth factor releasing scaffolds for tissue engineering: Scaffolds can 
be either immobilized with cell specific ligands for cell adhesion, or encapsulated with growth factors or 
DNA to promote cell proliferation and morphogenesis [Adapted from Ref. 1 with permission © Elsevier 
Science BV]. 
2. Meta analysis of leading research reports 
2.1. Local drug delivery for neuroprotection and tissue repair 
In a series of studies, Shoichet et al., (2006, 2009a, 2009b) demonstrated the potential of 
hyaluronic acid-methyl cellulose (HAMC) blend as an injectable scaffold for the delivery of 
bioactives to an injured spinal cord, via an intrathecal injection, in conjugation with 
providing necessary support and microenvironment for the proliferation of neural cells. The 
studies were conducted in the backdrop of three most common strategies for localized 
intrathecal delivery viz. a bolus injection, a minipump delivery, and an injectable gel that 
localizes release to the site of injection. The first method pose a challenge in terms of the 
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effects being short-lived due to washing-out of the therapeutic molecule by cerebrospinal 
fluid and the second one being invasive and may lead to complication ranging from device 
blockage to infection. The novel HAMC blends’ strategy provided a potential solution 
(Table 1) through the design of a shear-thinning based gel with an inherent property of 
increase in gel strength with an increase in temperature fast gelling [Figure 2]. 
 
S. No. Design criteria Advantage
1. Fast gelling localized delivery to the site of injection; no spread-out 
with the cerebrospinal fluid (CSF) flow 
2. Injectable through 30G 
needle 
minimally invasive surgery 
3. Non-cell adhesive minimization of scar formation in the intrathecal space 
4. Degradable no need for scaffold removal afterwards 
5. Biocompatible minimized foreign body reaction 
Table 1. Design criteria for an injectable scaffold architecture 
 
Figure 2. A) Elastic and viscous moduli of injectable gels at 1Hz using a rheometer with a cone and plate 
geometry (●) 7%MC G’, (○) 7%MC G”, (■) 9%MC G’, (□) 9%MC G”, (▲) HAMC G’, (∆) HAMC G”, (▼) 
acet-HAMC G’, and (◊) acet-HAMC G”. B) Thixotropic loop of injectable gels at 37°C (●) 7%MC, (■) 
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9%MC, (∆) HAMC, and (◊) acet-HAMC. C) In vitro degradation in aCSF of (●) 7%MC, (■) 9%MC, (∆) 
HAMC, and (◊) acet-HAMC determined by change of dry mass over time. D) Parasagittal section of rat 
spinal cord rostral to site of injection shows that the fluorescent HAMC is localized in situ in the intrathecal 
space where it was injected [Adapted from Ref. 4 with permission © Elsevier Science BV]. 
In a typical experiment, 2% HA was blended with 7% MC and the gelation mechanism, 
degradation profile, and cell adhesion were studied in vitro. Additionally, in vivo studies 
were carried out for testing the injectability, biocompatibility and therapeutic efficacy (2006). 
Furthering the study, the potential of HAMC blend for the delivery of neuroprotectant such 
as nimodipine and erythropoietin were investigated experimentally. Specifically, 
nimodipine-loaded gels yielded particle size-dependent biphasic release profiles suggesting 
the accelerated delivery of poorly soluble drugs with tuneable release rates. In an another 
report, in vitro erythropoietin release studies revealed a 16 h release profile with the implant 
showing reduced cavitation after spinal cord injury along with enhanced neuronal number 
proving the potential of HAMC in neuroprotection after neural injury [2-4]. 
2.2. Multifunctional, multichannel bridges that deliver neurotrophin encoding 
lentivirus 
Tuinstra at al., 2012, addressed the neural injury regeneration challenge by proposing a 
“gene delivery-biomaterial combination” strategy to surpass the “multiple barriers limiting 
regeneration”. Spinal cord injury induced neuron and oligodendrocyte cell death, 
demyelination, inflammation, and deposition of a glial scar are attributed to insufficient 
trophic factor support, and up-regulation of axonal growth inhibitors. To overcome the 
deficiency of trophic factors, peripheral nerve implants are preferred due to their biograft-
architecture and secretion of trophic factors by cells such as Schwann cells. However, the 
source limitation and the ill-defined contribution of the architecture and cell-secreted factors 
led to the requirement of systems and strategies capable of recapitulating their effects. To 
overcome the challenges, the delivery of lentiviral vectors (encoding neurotrophin-3 (NT-3) 
and brain derived neurotrophic factor (BDNF)) from multiple channel bridges was 
proposed as a combinatorial approach to promote regeneration in the injured SC. 
Interventionally, the lentivirus was immobilized to hydroxyapatite nanoparticles and then 
loaded into poly(lactic acid-co-glycolic acid) (PLGA) bridges for implantation into a rat 
spinal cord lateral hemisection and the axonal growth and myelination were characterized 
as a function of time, treatment, and location within the bridge. The strategy was aimed at 
(a) providing mechanical stability to the injured tissue, (b) channels directing the axonal 
elongation, (c) supporting cell infiltration, (d) preventing cavity formation secondary to the 
initial injury, (d) limiting scar formation. Interestingly, the cells were aligned with the major 
axis of the bridge providing a directional signal for regenerating axons [5]. 
2.3. In situ gelling hydrogels for local delivery of BDNF after spinal cord injury 
Over the last decade, a research group led by Ravi V. Bellamkonda at Wallace H. Coulter 
Department of Biomedical Engineering, Georgia Institute of Technology and Emory 
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University, Atlanta, USA, has emerged as a leading authority working towards the 
development of neurological biomaterials and therapeutics especially focusing on neural 
injuries. Jain et al., 2006, developed an agarose in situ gelling three-dimensional (3D) 
scaffold capable of initiating axonal growth in 3D. To this 3D scaffold was added 
neurotrophic factor BDNF-loaded lipid microtubule (40μm in length and 0.5μm in diameter) 
for local release of the bioactive. The individual benefits incurred by the components are 
structured in Table 2. Spinal cords treated with agarose/BDNF displayed no axonal bulbed-
up morphology and the axons crossed the interface into the hydrogel scaffold based on the 
NF-160kDa staining data analysis where NF-160 kDa intensity was significantly greater than 
the agarose-treated spinal cords at the interface [6]. 
 
Agarose scaffold Brain derived neurotrophic factor 
Biocompatible: does not cause an adverse 
reaction when implanted in vivo, 
encouraged neurite growth into the scaffolds  
can be optimized for maximum axonal 
outgrowth through manipulation of the 
porosity and mechanical properties,  
reduced the reactivity of the astrocytes and 
the production of chondroitin sulfate 
proteoglycans (CSPGs)  
Support cell migration  enhanced the ability of regenerating fibers to 
enter the permissive hydrogel scaffold  
can be utilized as part of a trophic factor 
delivery system with embedded sustained 
release vehicles, 
acted as a chemo-attractant for the axons to 
cross the interface 
can be used to bind protein to its backbone 
for spatial control 
reduces the minimal inflammatory response 
agarose gels generate in vivo  
Table 2. Salient features of the in situ gelling hydrogel components 
2.4. Neurite extension in anisotropic LN-1 scaffolds 
An in vitro study by Dodla and Bellamkonda, the importance of directional cues for neural 
regeneration was proposed. The hypothesis was based on the performance outcomes of 
autografts where the researchers theorized that “anisotropic hydrogel scaffolds with gradients 
of a growth-promoting glycoprotein/extracellular matrix protein, laminin-1 (LN-1), may 
promote directional neurite extension and enhance regeneration”. The scaffolds were fabricated 
via photochemical coupling approach wherein LN-1 was immobilized onto three-dimensional 
(3D) agarose scaffolds in gradients of differing slopes. A significant increase in the Dorsal root 
ganglia (DRG) neurite extension rates were observed in case of anisotropic scaffolds as 
compared to their isotropic analogues proving the importance and potential of built-in 
directional cues for guided tissue or nerve regeneration [7]. In line with the functionalized 
scaffold properties developed above, Crompton et al., 2007, described the potential of 
Polylysine-functionalized chitosan as an in vitro substrate, scaffold for cortical cells, and for 
neural tissue engineering as an injectable scaffold. The functionalized polysaccharide polymer 
was rendered thermoresponsive by ionic gelation mechanism of glycerophosphate. In first of its 
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kind study of chitosan-GP network gels on neural tissue, the 3D culture model showed that the 
survival of cells on chitosan/GP was less than the PDL-modified chitosan/GP justifying the 
inclusion of PDL as functionality for neural applications [8].  
2.5. Topical delivery of Tx-MP-NPs into the contusion injured spinal cord 
The delivery of bioactives on the site of neural injury can be achieved by various means 
including intravenous delivery eventually passing through blood brain barrier and reaching 
the site of action or through intrathecal/intracranial injection for localized delivery. Targeted 
delivery is an additional option but not much tried and tested for CNS injuries. The i.v. 
strategy encompasses the probability of inefficiency as compared to the localised delivery 
but invasiveness is a drawback for the later intervention. Chvatal et al., 2008, and later Kim 
et al., 2009, reported the therapeutic effectiveness of nanoparticle-mediated localized 
methylprednisolone (MP) delivery for spinal cord injury intervention. These studies tested 
the therapeutic effect of MP-loaded PLGA nanoparticles, incorporated into an agarose gel, 
in in vivo models of spinal cord injury. The first study by Chvatal et al, 2008, concentrated 
on the spatial distribution of MP along with the acute anti-inflammatory effect. In a typical 
fabrication, the drug was first conjugated with Texas-red cadaverine (Tx, Biotium) allow its 
visualization in and around an injured spinal cord. Thereafter, the PLGA nanoparticles were 
prepared using a double emulsion method followed by their incorporation into the agarose 
gel. Two different types agarose gel were used: denser gel without nanoparticles (SeaKem) 
and gel containing nanoparticles (SeaPlaque) as shown in Figure 3. 
According to Figure 4; the drug-indicator conjugate revealed a slow release over six days 
and the data was used to determine the amount of Tx-MP released from the gel-embedded 
NPs showing a continual release pattern. The release was probably due to the gradual 
degradation of PLGA polymeric structures. In this way, a continual delivery of MP can be 
provided to the injured spinal cord thereby exerting its anti-inflammatory action with a 
single administration and hence can provide much needed lipid-peroxidation inhibition 
during the initial and acute phase of secondary injury. To further simulate the in vivo 
environment, the in vitro release studies of Tx-MP from NPs embedded in agarose 
hydrogels was examined by co-incubation with LPS-stimulated primary rat microglia. The 
quantification of nitric oxide (NO) release from the microglia at different time points, 24, 72, 
and 96 h, showed that the cells treated with Tx-MP-NPs had significantly reduced NO 
production as compared to the cells treated with Saline NPs (as a negative control) further 
proving that the hydrogel-based delivery system (i.e., NPs embedded in agarose gel) can be 
used as an MP depot.  
The quantification of spatial distribution of Tx-MP in the contusion injured spinal cord 
revealed that MP diffused up to 1.5mm deep and up to 3 mm laterally into the injured 
spinal cord within 2 days. Other significant observations of this study included decreased 
early inflammation, reduction in the number of ED-1þ macrophages/activated microglia, 
diminished expression of pro-inflammatory proteins such as Calpain and iNOS, and finally 
reduced lesion volume within 7 days after contusion injury [9]. 
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Figure 3. a) Schematic showing the Tx-MP-NP embedded gel is placed directly onto the injury site, on top 
of the dura. The denser gel is injected on top and quickly cooled to hold the NP embedded gel in place and 
minimize outward diffusion of Tx-MP. b) Methylprednisolone-encapsulating PLGA nanoparticles (MP-
NP): SEM image of the lyophilized MP-NPs. c) Schematic of topical and local delivery of the MP-NPs onto 
dorsal over-hemisection lesioned spinal cord [Adapted from Ref. 9 with permission © Elsevier Science BV]. 
 
Figure 4. In vitro characterization of Tx-MP-NPs. (A) Release profile of Tx-MP over 6 days in vitro. 
Plotted is the amount of MP released every 24 h. (B) Bioassay showing the amount of nitrite in the 
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media surrounding LPS-activated microglia that had been treated with gels containing either MP-NP, 
Tx-MP-NP, Saline-NP, or nothing. This represents the amount of NO produced by microglia in each of 
these conditions for 4 days [Adapted from Ref. 9 with permission © Elsevier Science BV]. 
2.6. Nanoparticle-mediated local delivery of methylprednisolone 
Further extending the above results, Kim et al., 2009, conducted a detailed histological and 
behavioural study of the developed local and sustained MP delivery through the use of 
biodegradable polymer-based nanoparticles. The following histological parameters were 
recorded: 
1. reduced the reactivity of pro-apoptotic proteins (Calpain and Bax) 
2. increased reactivity of anti-apoptotic protein (Bcl-2) at the lesion site 
3. reduced iNOS (a key mediator of inflammation and neurotoxic effects expression 
4. ratio of Bcl-2 to Bax, a key determinant of neuronal commitment to apoptosis, was 
increased indicating that MP treatment reduced the mitochondria-mediated cell death 
pathway.  
These results suggest that sustained MP delivery by slow release MP-NP can reduce the 
reactivity of the injury-related proteins. Furthermore, MP-NP treatment produced 
significantly improved functional outcomes within one week after injury wherein MP-NP-
treated groups performed significantly better in the beam walking test. 
In conclusion, following advantages of MP-NP local delivery over conventional systemic 
delivery were proposed:  
1. Better therapeutic effect as compared to systemic MP delivery; 
2. More efficient, targeted delivery to the injury site as the MP delivery via systemic 
administration is influenced by the short pharmacokinetic half-life of intravenous MP 
(2.5–3 h) and P-glycoprotein-mediated exclusion of MP from the spinal cord necessitating 
a high-dose MP regimen. However, a significantly lower dose was required using 
nanoparticle-encapsulated MP (approximately 400 mg/ animal) and delivering this dose 
locally onto the target tissue. Additionally, this significantly enhanced the therapeutic 
effectiveness of MP by increasing the local dose levels at the target site; 
3. Potential to adjust delivery rate or duration since the MP release profile from 
nanoparticles can be controlled through the composition of the biodegradable polymer, 
the rate, amount, or duration of delivery can be adjusted; 
4. Stable formulation in form of injectable and lyophilized fine (submicron) powder 
formulation (unlike cell-based therapies). The formulation can be stored as a 
lyophilized fine powder and then easily suspended in saline or embedded in hydrogel 
and locally delivered onto the lesion site [10]. 
2.7. Sustained delivery of thermostabilized chABC 
Furthering their study on the involvement of various axonal growth promoters and 
inhibitors, Bellamkonda and co-workers targeted Chondroitin sulfate proteoglycans, a major 
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class of axon growth inhibitors that are up-regulated after spinal cord injury and contribute 
to regenerative failure, via the use of Chondroitinase ABC (chABC) capable of digesting 
glycosaminoglycan chains on CSPGs thereby overcoming the CSPG-mediated inhibition. 
The formulation problem concerned with chABC is the loss of its enzymatic activity 37 °C, 
necessitating the use of repeated injections or local infusions for a prolonged period making 
it clinically inefficient. Lee et al., 2010, designed a thermostabilized chABC and developed a 
system for its sustained local delivery in vivo thereby resolving the problem to a great extent 
as the novel thermostabilized chABC retained its biological activity at 37 °C in vitro for up 
to 4 weeks [Figure 5]. 
 
Figure 5. Enhanced thermal stability of chABC with trehalose, and sustained chABC release with 
lipidmicrotubes. (A) SDS-PAGE assay of enzymatic activity of chABC. (B) Kinetic analysis of chABC 
deactivation by DMMB assay. The dotted line represents the calculated deactivation curve of chABC in 
1× PBS. (C) Enzymatic activity of post released chABC (Δ) and penicillinase (○) with 
trehalose/microtubes [Adapted from Ref. 11 © Proceedings of National Academy of Science (PNAS)]. 
Briefly, chABC was thermostabilize using the sugar trehalose and a hydrogel-microtube 
based delivery system was used for the sustained local delivery of chABC in vivo [11]. Key 
finding of the study included: 
a. Trehalose Significantly Enhances chABC Thermal Stability and Prolongs Enzyme 
Activity 
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b. Temperature stabilization of chabc by trehalose was due to conformational stability 
c. Thermostabilized chABC (TS-chABC) retains its ability to digest CSPGs in vivo 2 weeks 
post-injury,  
d. CS-GAG levels remain significantly depleted at the lesion site for at least 6 weeks post-
SCI. 
e. Enhanced axonal sprouting and functional recovery is observed after topical delivery of 
agarose-microtube-chabc scaffolds after SCI 
f. Animals treated with thermostabilized chABC in combination with sustained 
neurotrophin-3 delivery showed significant improvement in locomotor function and 
enhanced growth of cholera toxin B subunit– positive sensory axons and sprouting of 
serotonergic fibers.  
g. chABC thermostability facilitates minimally invasive, sustained, local delivery of 
chABC that is potentially effective in overcoming CSPG-mediated regenerative failure. 
2.8. Sustained delivery of activated Rho GTPases and BDNF 
In the next stage of their Chondroitin sulfate proteoglycans targeting, Bellamkonda and co-
workers fabricated constitutively active (CA) Rho GTPases, CA-Rac1 and CA-Cdc42, and 
BDNF loaded 1,2-bis-(tricosa-10,12-diynoyl)-sn-glycero-3-phosphocholine lipid microtubes 
for the sustained release of bioactives to the lesion site for the alleviation of CSPG-mediated 
inhibition of regenerating axons. The lipid tubules were further loaded into an in situ gelling 
agarose-protein architecture similar to previous studies where nanoparticles were 
incorporated into an agarose injectable gel. The sustained release characteristics of the 
developed system were characterised both in vitro and in vivo BDNF was conjugated to 
rhodamine for its in vivo quantification. As depicted in Figure 6, 3 mg of BDNF was 
released within the first 24 h followed by a cumulative release of 4mg within the first 3 days. 
After this initial burst release, approximately 3ng/day of BDNF was released for the 
subsequent 11 days. For in vivo release study, microtubes loaded with BDNF/Rhodamine 
embedded in the agarose were injected into the spinal cord cavity. Spatial quantification of 
BDNF/Rhodamine displayed its presence in the spinal cord tissue between 1 to 2 mm 
proximal to the lesion site (Fig. 1B). An overlap of ED-1+ cells (green) with the BDNF-
Rhodamine demonstrated co-localization and subsequent engulfment of the BDNF-
Rhodamine by the ED-1+ cells. Additionally, BDNF-Rhodamine was double labelled with 
DAPI to visualize cell nuclei confirmed the presence of neurotrophins [12]. In conclusion, 
the study utilized the hydrogel/microtubule scaffold delivery system to deliver BDNF, CA-
Cdc42, or CA-Rac1 to decrease the sensitivity of growth cones to CSPGs, and promote 
axonal growth through CSPG-rich regions at the lesion site based on following three 
phenomena: 
1. The use of the in situ gelling hydrogel allows the lesion cavity to be conformally filled.  
2. The lipid microtubes allow slow release of therapeutics from the hydrogel over time.  
3. This strategy allows neuroprotective or axonal migration stimulators to be delivered 
locally over time. 
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Figure 6. In Vitro and In Vivo Diffusion of BDNF. A. In vitro release assay of BDNF over the first 2 
weeks. The graph shows that an initial burst released 4 mg of BDNF within the first 3 days. An average 
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of 3 ng/day of BDNF was released for the following 11 days. The data represent mean 6 SEM B. An 
image of the proximal region of a spinal cord section after delivery of BDNF/Rhodamine at 46. The 
206images labelled 1 and 2 are outlined with white boxes in A and demonstrate that BDNF/Rhodamine 
diffused approximately 2 mm proximal to the lesion site. The dashed line represents the interface 
between the spinal cord and scaffold. White arrows indicate BDNF/Rhodamine. C. A 206image of ED-1+ 
cells (green) and BDNF-Rhodamine (red). The image shows some overlap demonstrating engulfment of 
the BDNF-Rhodamine by the ED-1+ cells. D. A 206image of DAPI (blue) and BDNF-Rhodamine (red) 
demonstrates that not all of the BDNF-Rhodamine is taken up by resident and migrating cells. 
Quantitative analysis of NF-160 intensity for the stained spinal cords. The spinal cords treated with CA-
Cdc42, CA-Rac1, and BDNF had significantly higher fluorescent intensity and also had extended further 
into the scaffold filled spinal cord cavity than the untreated and agarose controls [Adapted from Ref. 12 
© PLoS ONE]. 
2.9. Multiple-channel scaffolds to promote spinal cord axon regeneration 
Moore et al., 2006, introduced a proposition regarding the use of a conjugation of molecular, 
cellular, and tissue-level treatments for spinal cord injury to elicit functional recovery in 
animal models or patients. In a tri-component study, multiple-channel biodegradable 
scaffolds were tested as a platform to investigate the effects scaffold architecture, 
transplanted cells, and locally delivered molecular agents on axon regeneration. 
Biodegradable polymers such as PLGA can provide a tissue scaffold, a cell delivery vehicle, 
and a reservoir for sustained drug delivery. Therefore, PLGA scaffolds were fabricated 
using injection moulding with rapid solvent evaporation.  
The scaffolds so formed have characteristic plurality of distinct channels running parallel 
along the length of the scaffolds with various customized channel sizes and geometries. 
Inherent to the channels were void fractions (as high as 89%) with accessible void 
fractions as high as 90% through connections 220mm or larger. Scaffolds degradation and 
bioactive release in vitro accounted for over a period of 30 weeks and 12 weeks, 
respectively. The degradation profile of PLGA scaffold demonstrated typical polyhydroxy 
acid characteristics as the scaffold molecular weight decreased steadily from 100% of the 
initial molecular weight down to 5% by 26 weeks of degradation. Interestingly, minimal 
mass loss was observed for the first 20 weeks. The next ten weeks culminated into a more 
precipitous mass loss generating a sigmoidal mass loss behavior typical for PLGA 
degradation. The negligible change in mass during initial phase corroborated well with 
the slight changes in morphology. However, the morphology of the degrading scaffolds 
changed drastically during the precipitous phase. The model drug, Fluorescein 
isothiocyanate (FITC-D), was incorporated using, mechanical mixing within the polymer 
scaffolds. However the method was quite effective for scaffold loading, an 
inhomogeneous dispersal appeared in the final fabricated scaffolds. A drug release-
scaffold degradation comparison in Figure 7 compared the mass and molecular weight 
degradation profiles with model drug release. An initial burst over the first 48 h was 
followed by a period of more steady release for 4 weeks. The sustained release continued 
for next 8 weeks after which little or no release was detected for the remainder of the 
degradation period. 
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Figure 7. Histological images of tissue cables within scaffold channels. (A) Histological cross section 
near rostral end of scaffold showing tissue cables within all seven channels. Boxed region is shown in 
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greater detail in D. (B) Histological cross section shown in A with channels segmented and displayed in 
color. (C) Orthographic, wedged view of 16 serial slices registered, segmented, and reconstructed to 
reveal 3-D structure of channels. (D) Histological cross section of boxed region in A; (E) Orthographic, 
wedged view of reconstructed channel shown in D, with segmented axon bundles displayed in color. 
(F) Degradation and FITC-D release profile. Mass or molecular weight change is indicated as a 
percentage of initial value at time zero. FITC-D release is indicated as a cumulative percentage of 
loaded drug [Adapted from Ref. 13 with permission © Elsevier Science BV]. 
The release of the drug progressed in corroboration with scaffold degradation. However, 
the inhomogeneity played its role as a very high variability was observed. The polymeric 
architecture was designed to act as a template for the arrangement of cells that may attract 
and guide regenerating axons rather than for guiding the regenerating fibers by providing 
an oriented surface. The delivery system was proposed to be flexible enough to provide 
incorporation of various drugs/biomolecule/bioactives that may add tropic attraction, 
neuroprotection, or reduce the inhibitory effects of secondary injury. Another important 
aspect of the study was to attest the effect of incorporation of Schwann cell in the scaffold 
as their harvesting, suspension, and distribution into scaffold channels is of critical 
importance in this field. Results indicated that Schwann cells were successfully harvested, 
suspended in Matrigel, and loaded into distinct channels, and that cells survived in 
culture under physiologic conditions within the scaffold. Axon regeneration was 
visualized by 3-D reconstruction of serial histological sections, an approach that appears 
useful for evaluation of regenerating tissue architecture as shown in Figure 7. The 3-D 
reconstructions demonstrated the arrangement of the seven channels containing 
regenerating axons, as well as live axon bundles within the channels. This novel depiction 
corroborated well with the channels which were found distributed as arranged by the 
scaffold, with scaffold and tissue in the spaces separating the channels, approximately. An 
important finding revealed that channels generally contained a centralized core of tissue 
containing axons and capillaries, surrounded by circumferential fibrous tissue. 
Furthermore, macrophages could be identified, due to their engulfment of neurofilament-
stained material [13]. 
2.10. Laminin and nerve growth factor-laden three-dimensional scaffold 
Yu et al., 1999, engineered Leminin-functionalized agarose hydrogel scaffolds for the 
stimulation of neuronal process extension based on the hypothesis that “substrate-bound 
neurite promoting extracellular matrix (ECM) proteins and chemo-attractive diffusible 
trophic factors influence and stimulate axon guidance and neurite extension”. The study 
indicated that the effect of LN-modified agarose gels on DRG/PC12 cell neurite outgrowth 
involves receptors for YIGSR/integrin/31 subunits, respectively. Additionally, 1,2-bis(10,12-
tricosadiynoyl)-sn-glycero-3-phosphocholine based lipid micro-cylinders were loaded with 
nerve growth factor (NGF), and embedded into agarose hydrogels which resulted in a 
directional neurite extension from DRGs in agarose hydrogels due to the presence of trophic 
factor gradients. The NGF-loaded lipid micro-cylinders released physiologically relevant 
amounts of NGF for at least 7 days in vitro based on a PC12 cell-based bioassay confirming 
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that the agarose hydrogel scaffolds can be used as biosynthetic 3D bridges capable of 
promoting regeneration across severed nerve gaps [14]. 
2.11. Agarose and methylcellulose hydrogel blends for nerve regeneration 
applications 
Taking leads from the research done by Shoichet and co workers and from Bellamkonda 
and co workers, Martin et al., 2009, designed injectable scaffold consisting of agarose and 
methylcellulose (MC) as the responsive polymers. The following rationale was cited in 
support of using a blend of MC and agarose instead of using agarose alone: the low melting 
point of agarose makes it difficult to use in vivo and hence need to be cooled after injection 
wherein blowing of gases onto nervous system tissue could potentially be harmful to 
neurons that survived the initial injury. The release of bioactive from such gelling mixtures 
was related to the dissolution of the scaffold itself under physiological conditions. In an 
interesting experiment the percentage of hydrogel dissolved was measured on day 1, 4, 7, 14 
and 28. Plain agarose dissolved completely when left in PBS in a 37 ◦C incubator for only 7 
days, making it difficult to record the percentage dissolved due to hydrogel instability. 
However, the blends were approximately 70% dissolved by the end of 28 days in the cycled 
PBS solution. Pristine 7% methylcellulose proved to be a weaker hydrogel that dissolves 
more rapidly than the hydrogel blends, dissolving over 75% in 28 days. This confirmed the 
applicability of the blend in comparison to individual polymers. Furthermore, the authors 
pointed that “the ease of creation, simplicity of delivery and use of natural biocompatible 
components that solidify naturally without the use of ultraviolet light or cross linkers add to 
the advantages of utilizing this blend” [15]. 
2.12. An injectable, biodegradable hydrogel for trophic factor delivery 
Piantino et al., 2006, devised a new method for an injectable based drug delivery system for 
the delivery of trophic factors to the injured neural tissues. The method utilized an injectable 
liquid polymer solution that crosslinks into a biodegradable, water-swollen hydrogel when 
photo-activated under visible light. The investigators described the uniqueness of their 
system over other systems as follows:(1) the system can provide constant and tailorable 
delivery of one or more growth factors to the precise site where needed; (2) reduce the 
possibility of host–graft rejection, as may occur with the use of live tissue or cell 
preparations; (3) does not involve viral vectors, which may induce an inflammatory 
response and which may require prolonged delays in achieving high levels of gene 
expression; and (4) does not involve the use of devices that can malfunction or cause 
infections (e.g., pumps or catheters). Briefly, degradable poly(ethylene glycol) hydrogels are 
formed from the radical polymerization of acrylated poly(lactic acid)-b–poly(ethylene 
glycol)-b–(poly lactic acid) (PLA-b–PEG-b–PLA) macromers. The network degradation and 
subsequent molecular release properties can be controlled by altering the network chemistry 
of these injectable hydrogels such as the number of degradable units and network 
crosslinking density by changing the macromer concentration). The degradation of the 
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hydrogels was postulated to be due to hydrolysis in the network crosslinks. The release 
profile of NT-3 in vivo was determined using ELISA and a peak was reported at the site of 
injury as early as 3 h after hydrogel administration. High concentrations over a distance of 1 
cm and more were cited site on day 6 followed by a decline to approx. one-third of 
maximum after 14 at 14 days. The NT-3 levels within the first few millimetres of the lesion 
site were in the range of 50 ng/ml/g of tissue when averaged over the entire tissue sample. In 
vitro release studies corroborated well with the inv vivo data with a burst release of ~40% 
over first 24 hours and a sustained release thereafter. Interventionally, NT-3, delivered via 
hydrogel in the vicinity of injured nerve terminals, was presumed to be transported 
retrogradely to cortical pyramidal cells thereby promoting axonal branching along with 
promoting plasticity of the raphespinal tract and finally promoting the outgrowth of 
descending pathways involved in locomotor control leading to the lesion size being slightly 
smaller in NT-3-treated vs. control animals as early as 1 day and 1 week post-lesion [16]. 
2.13. Hydrogel scaffold and microspheres for supporting survival of neural stem 
cells 
To develop a biomaterial composite for promoting proliferation and migration of neural 
stem cells (NSCs) and to rescue central nervous system (CNS) injuries, Wang et al., 2011 
constructed a NSCs-cultured delivery system based on crosslinked hyaluronic acid (HA) 
hydrogels, containing embedded BDNF and vascular endothelial growth factor (VEGF)-
loaded poly(lactic-co-glycolic acid) (PLGA) microspheres for controlled delivery as well as 
angiogenesis on the materials. The study was designed on the drawbacks of previous 
studies that have shown an intrinsic ability of neural stem cells (NSCs) to regenerate in 
various neurological diseases’ intervention. The most important among these were the low 
viability and undesired differentiation of the grafted NSCs and also the glial scar formation. 
In addition to these, the deficiency of neurotrophic factors and growth factors following the 
CNS may also contribute to failure of neural regeneration. The in vitro release kinetics study 
by ELISA measured the loading of BDNF and VEGF in microspheres as 0.10 and 0.34 μg/mg 
microspheres, respectively, corresponding to 52% and 84% loading efficiency making the 
loading efficiencies of HA gel composites in the range of 17.4 and 56.6 ng/mg, respectively, 
when embedded with microspheres. Interestingly, no burst release characteristic to the 
PLGA microspheres was within the period of 6 days wherein bioactives were released from 
the microspheres constantly and cumulatively. The thorough washing of the microspheres 
was believed to overcome the burst release of the proteins from the surface and provided a 
slow and linear release profile during the test period. During the first week of the study, 
about 20–30% of the loaded proteins were release possible by diffusion from areas near the 
surface as the degradation of PLGA was insignificant during initial phases. In contrast, the 
release of growth factors from the hydrogel embedded with microspheres revealed an initial 
“burst” followed by a stable release phase. This was attributed to the fact that released 
factors might have remained in the hydrogel during the cross-link processing leading to the 
diffusion through the hydrogel matrix. However, the cumulative amount of bioactive 
release was reduced to 12% and 13% of total loading as compared to 20-30% in case of 
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microspheres alone which was postulated to be due to the presence of the surrounding HA 
hydrogel as a delayed or deposited effect on the release profile of the biofactors [17]. 
2.14. Controlled release of Neurotrophin-3 from fibrin-based tissue engineering 
scaffolds 
Pathologically, the ability of chronically injured supraspinal axon tracts to regenerate 
decreases if intervention is delayed for too long. The barriers to axonal regeneration in case 
of a chronically injured spinal cord are reported to be overcome interventionally by using a 
combination of diffusible growth stimulating molecules and a favourable growth 
stimulating extracellular matrix such as the use of a continuous transgenic delivery of 
neurotrophic factors from engineered cells that also secrete extracellular matrix (ECM) is 
conducive to regeneration [18]. However, there is a limitation of this strategy as that the 
growth is limited to the regeneration of axons into the transplant site, the source of the 
growth stimulating neurotrophins, and the axons fail to regenerate back into host tissue. 
Sakiyama-Elbert and co workers, 2009, coined the need for temporary controlled release of 
growth-stimulating neurotrophins that not only promote axon growth into the lesion but 
also foster growth into healthy spinal cord tissue thereby connecting the newly grown tissue 
to the neural tissue that survived the injury. The intervention consisted of delayed treatment 
of SCI with controlled release of neurotrophin-3 (NT-3) from fibrin scaffolds providing a 
supportive regenerative environment, reducing the accumulation of reactive astrocytes 
surrounding the lesion and enhancing the presence of neural fibers within the lesion. The 
heparin-based delivery system (HBDS) developed earlier by the investigators [19], was 
utilized as it forms non-covalent interactions between neurotrophins, heparin, and a 
covalently linked bi-domain peptide (ATIII peptide), which can be incorporated into the 
fibrin scaffold and allow for the controlled release of growth factors from the scaffolds. The 
controlled released of the biofactor from the fibrin scaffold was assessed in terms of 
quantification of neural fiber density, astrocyte density, and chondroitin sulfate 
proteoglycan density along with macrophage/microglia immune profile analysis. The final 
results demonstrated that controlled release of NT-3 promotes increased neural fiber density 
within the lesion and decreased reactive astrocyte staining around the lesion of subacute SCI 
(2 weeks after the injury) at a dose of 500 ng/mL of NT-3 with HBDS [20]. These results were 
in corroboration with the earlier reports where the NT-3/HBDS was employed in an acute 
SCI (immediately after the injury) model wherein the it promoted a significant increase in 
the density of neural fibers sprouting [21-23]. 
2.15. Nerve guidance channels as drug delivery vehicles 
However, safe and effective use of pro-regenerative molecules requires a localized, controlled 
and sustained delivery to the site of neural injury. However, there are many challenges 
pertaining to the various approaches available in the neural arena as described in Table 3. 
To overcome the challenges shown in the table above, Piotrowicza and Shoichet, 2006, 
developed a liquid–liquid centrifugal casting process which enables the formation of nerve 
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guidance channels (NGCs) from acrylate-based hydrogels such as 
poly(hydroxylethylmethacrylate-co-methylmethacrylate) or P(HEMA-co-MMA). The NGCs 
themselves were fabricated by a liquid–liquid centrifugal casting process and the protein 
incorporation strategies were compared in terms of protein distribution and nerve growth 
factor (NGF) release profile. The centrifugal casting process is based on the following 
phenomenon: Phase separation of the polymer phase from the monomer formulation during 
polymerization in a rotating cylindrical mould and hence the denser polymer phase is 
pushed to the periphery by centrifugal forces, where it gels forming a tube. The NGCs thus 
formed were semipermeable, soft and flexible, and matched the modulus of the nerve or 
spinal cord.  
 
S. No. Approaches Challenge 
1. Systemic administration short half-lives and high potency of many biomolecules, 
and delivery to the CNS is further limited by the blood–
brain barrier 
2. osmotic mini-pumps infections or tissue damage, pump failure due to 
catheter dislodgement or occlusion, as well as drug 
instability in the pump reservoir 
3. local administration as 
growth factor solutions 
factors lose bioactivity in solution 
4. local administration as 
matrices saturated with 
growth factors 
easily leak from the channel during the implantation 
procedure 
5. NGCs prepared by dip-
coating or solution casting 
the creation of a non-symmetric growth factor 
concentration profile within the lumen of the NGC 
Table 3. Challenge inherent to various bioactive administration approaches 
The investigators formulated three different approached for the delivery of nerve growth 
factor (NGF) using Nerve guidance channels (NGCs constituted with of poly(2-
hydroxyethyl methacrylate-co-methyl methacrylate), P(HEMA-co-MMA) as the polymeric 
platform to facilitate regeneration after transection injury to the spinal cord: (1) NGF was 
encapsulated (with bovine serum albumin (BSA)) in biodegradable poly(D,L-lactide-co-
glycolide) 85/15 microspheres, which were combined with a PHEMA polymerization 
formulation and coated on the inside of pre-formed NGCs by a second liquid–liquid 
centrifugal casting technique; (2) pre-formed NGCs were imbibed with a solution of 
NGF/BSA and (3) NGF/BSA alone was combined with a PHEMA formulation and coated on 
the inside of pre-formed NGCs by a second liquid–liquid centrifugal casting technique. The 
channels imbibed with NGF showed no sustained release of NGF as was achieved from 
NGCs with either NGF-loaded microspheres or NGF alone incorporated into the inner layer 
with values of 1040 pg/cm, 220 pg NGF/cm, and 8624 pg/cm, respectively, after 28 days 
[Figure 8]. As a key finding, the release of the bioactive from the conduits was dependent on 
the slow-degrading characteristic of the microspheric system as well as on the “maximum 
amount of microspheres” that could be incorporated into the cylindrical structure. Another 
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important finding of the report was that the liquid–liquid centrifugal casting process 
demonstrated potential towards localized and controlled release of multiple factors key to 
tissue regeneration after neural injuries [24]. 
 
Figure 8. Cumulative release profile of NGF (pg/cm of NGC) over a 28-day period from NGCs (a) 
coated with an inner layer of PHEMA containing NGF-loaded PLGA 85/15 microspheres; (b) imbibed 
with NGF; and (c) coated with an inner layer of PHEMA containing directly entrapped NGF [Adapted 
from Ref. 24 with permission © Elsevier Science BV]. 
2.16. Self-assembling peptide nanofiber scaffold enhanced with RhoA inhibitor 
In a recent study, Zhang et al., 2012, focused on two major targets for axonal regeneration 
after a spinal cord injury: 
a. The reconstruction of the gap in the injured spinal cord  
b. Inactivation of RhoA to ameliorate the hostile microenvironment perilesion  
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To achieve these targets, Zhang et al., 2012, transplanted self-assembling peptide nanofiber 
scaffold (SAPNS) based local delivery of RhoA inhibitor to the lesion sites after acute spinal 
cord injury centred on their previous reports wherein the SAPNS had shown multiple 
regeneration-facilitating properties to improve the recovery of the injured spinal cord and 
brain and that SAPNS has potential for controlled bioactive release. The study was based on 
the hypothesis that this novel combination might act by providing regrowth-promoting 
scaffold reducing the physical obstacles after injury (characteristic SAPNS capability of 
filling the cavities and alleviating glial scarring) and the RhoA inhibitor released from the 
combination implants may exert a therapeutic effect conducive for axonal regrowth.  
As depicted in Figure 9, the SAPNS implants, with or without CT04 incorporation, 
reconstructed the injured spinal cord whereas a significant gap was developed in the lesion 
site in the saline group. Additionally, the implants integrated closely with the surrounding 
host tissue with no cavities or gaps occurring between the implants and host tissue. Another 
striking finding was the presence of the cells such as fibroblasts, which mainly clustered in 
the centre of the lesion area and formed collagen fibers, along with lymphocytes, 
macrophages, astrocytes, and microglias scattered among the fibroblasts. The growth of 
such cellular mass may further hindered the cavity or cysts formation- a major cause of 
anatomical disconnection after SCI. On the drug delivery note, SAPNS delivery of CT04 
significantly improved the axonal regrowth. Based on fluorescent characteristics of dextran, 
it was incorporated into SAPNS to track the spread-out and diffusion of the bioactive in the 
lesion site. Seven days after the transplantation of the SAPNS incorporated with Dextran, 
significant fluorescence was observed into the surrounding host cord from the SAPNS, 
while the implant still retained high fluorescent signal confirming the release of chemicals 
from SAPNS and indication that SAPNS can effectively serve as a platform for further 
controlled release of exogenous therapeutic molecules of interest. In conclusion, the SAPNS 
delivery system proved to be capable of minimal risk of carrying biological pathogens or 
contaminants, providing 3-dimensional environment constructed for cell growth and 
migration, minimal cytotoxicity to the host, no apparent immune response, easy conformity 
to the various shape of lesion cavities, and immediate haemostatic and controlled drug 
release properties [25].  
2.17. Sustained delivery of chondroitinase ABC from hydrogel system 
As explained earlier in this report, chondroitin sulfate proteoglycans (CSPGs) are among the 
principal factors responsible of axon growth inhibition and they contribute to regenerative 
failure, promoting glial scar formation in an injured spinal cord. Chondroitinase ABC 
(chABC), although capable of digesting these proteoglycans leading to the degradation of glial 
scar and favoring axonal regrowth, suffers from delivery drawbacks such as administration 
being invasive, infection-prone and clinically problematic. Rossi et al., 2012, developed an 
agarose-carbomer (AC1) hydrogel, which they previously used in SCI repair strategies [26-28], 
as a delivery system capable of an effective chABC administration based on following 
considerations: ability to include chABC within its pores and the possibility to be injected into 
the target tissue; and release kinetics and the maintenance of enzymatic activity can be  
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Figure 9. The implants of various SAPNS reconstructed the injured spinal cord. (a–d)Macroscopic 
observations of lesion sites immediately after surgery. (a) Sham surgery; (b) saline group; (c) SAPNS 
with vehicle group; (d) SAPNS+CT04 combination group. (e) HE staining shows the lesion area was 
reconstructed 12 weeks after SAPNS transplanted. (f) HE staining shows various cells in the grafted 
scaffold, which include fibroblast (black arrow), macrophage (yellow arrow), and lymphocyte (arrow 
head). (g–i) Immuno-staining shows the GFAP-positive astrocytes (g), IBA1 positive microglias (h) and 
ED1 positive macrophages (i) in the grafted scaffold. (j) shows the Dextran, a red fluorescent dye, was 
partially diffused from the mixture of SAPNS and Dextran at 7 days after transplantation [Adapted 
from Ref. 25 © Hindawi Publishing Corporation]. 
positively assessed. Additionally, being a hydrogel, AC1 had its own advantages in terms of 
(I) the ability to retain water; (II) mimicking living tissues; (III) high biocompatibility; and (IV) 
the possibility to allow precisely controlled release rates. As demonstrated in Figure 10, AC1 
appeared to be a chemical gel synthesized through a statistical block polycondensation 
between Carbomer 974P and agarose. chABC was loaded before the sol/gel transition resulting 
in its physical entrapment within the three-dimensional polymeric network of the gel. 
Macroscopically, a highly entangled nanostructure was confirmed by ESEM analysis proving 
its ECM mimicking nature. In brief, Carbomer 974 P provided the main cross-linking 
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properties via its carboxylic groups which in turn reacted with hydroxyl groups from agarose 
leading to the formation of a three dimensional matrix. The in vitro release kinetics displayed 
typical hydrogel characteristics wherein a rapid initial release of Tx was observed during the 
initial phases due to a high concentration gradient possible caused by: molecules placed near 
solvent-hydrogel interface that may rapidly escape into the supernatant solution; molecules 
diffusing through the large pores of the hydrogel in comparison to the molecules diffusing 
through smaller pores. The burst release was followed by slower release and eventually 
forming a plateau. After this initial burst, the release became slower and reached a plateau - 
steady state condition - after 7 days. Importantly, the whole amount of Tx loaded was release 
eventually confirming the absence of any stable bonds between hydrogel polymeric network 
and loaded Tx. Furthermore, it confirms the hydrogel’s capacity to deliver even those 
molecules that are deeply entrapped in its core [29].  
 
Figure 10. Carbomer 974P (A); agarose (B) were chemically cross-linked to form hydrogel in phosphate 
buffer saline solution. Esterification, hydrogen bonding and carboxylation bring polymer chains 
statistically closer, thus creating a stable heterogeneous structure. The gelling solution was 
homogenized together with chondroitinase ABC (chABC); (C) above sol-gel transition temperature. 
From a macroscopic point of view the resulting material appears as in (D). From a microscopic point of 
view the hydrogel is densely structured, as observable by ESEM analysis. [Adapted from Ref. 29 © 
MDPI Publishing] 
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2.18. Injectable functionalized self-assembling scaffold 
Self-assembling peptides (SAPs) perfectly mimic the extra-cellular matrix’s structural and 
conformational characteristics; can be injected into the lesion site; are reabsorbable; and have 
sites for biofunctionalizations making them a perfect nanomaterial for application in 
regenerative. Cigognini et al., 2011, explored the biofunctionalizability of self-assembling 
peptides to enhance the in vitro neural stem cells survival and differentiation. This injectable 
nanofibrous gel was composed of RADA16-I functionalized with a bone marrow homing 
motif (BMHP1) which was further optimized via the insertion of a 4-glycine-spacer for 
amelioration of scaffold stability and exposure of the biomotifs. The scaffold was injected 
immediately after contusion in the rat spinal cord was evaluated for its putative 
neuroregenerative properties in terms of early effects by semi-quantitative RT-PCR and the 
late effects by histological analysis. The axon regeneration/sprouting across the cyst was 
quantified by the presence of GAP-43 positive fibers and the relative value of GAP-43 
immunopositive area was represented as percentage of the total cyst area (Figure 11Bi). 
Interestingly, a significantly greater synthesis of GAP-43 in 4G-BMHP1 group (12.9462.03% 
of the whole cyst area) in comparison with saline (6.3361.7% of the whole cyst area) and SCI 
control (5.8461.29% of the whole cyst area) groups was originated (Figure Bii). The chronic 
inflammatory response, evaluated by counting macrophages into the lesion site (Figure 
11Ci), revealed that several infiltrating CD68 immunopositive cells in all groups, indicating 
that at the late phase of the injury the scaffold didn’t significantly affect the host immune 
response (Figure Cii). Similarly, cyst and cavities extent, measured on hematoxylin-eosin 
stained sections (Figure 11Ai), was similar in all groups (Figure Aii) wherein no significant 
differences were observed among treatment and both control groups when the cavities size 
within the cyst excluding strands of connective tissue (trabeculae) were measured (Figure 
Aiii). Conclusively, the injectable SAP based scaffold demonstrated potential for enhanced 
matrix remodelling, release of trophic factors, cell migration and basement membrane 
deposition leading to an increased number of regenerating/sprouting axons after incomplete 
SCI. Apart from the neuro-compatibility, the scaffolds were able to fill the cavities at SCI site 
with implications leading to a good matrix for the in vivo delivery of growth factors and/or 
stem cells into the injured CNS [30]. 
2.19. Effects of dibutyryl cyclic-AMP on survival and neuronal differentiation of 
neural stem/progenitor cells 
Enthused by the poor control over transplant cell differentiation and survival, Kim et al., 
2011, introduced a combinatorial approach wherein the cell transplantation therapy was 
adjoined with a bioactive release platform. Firstly, dibutyryl cyclic-AMP (dbcAMP) was 
encapsulated within poly(lactic-co-glycolic acid) (PLGA) microspheres and embedded 
within chitosan guidance channels. Secondly, neural stem/progenitor cells (NSPCs) were 
seeded in fibrin scaffolds within the channels (Figure 12). The idea behind the study was to 
determine whether dbcAMP, which can influence the in vitro differentiation of NSPCs into 
neurons, will be able to enhance survival of transplanted NSPCs through prolonged 
exposure either in vitro or in vivo through its controlled release from microspheres in  
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Figure 11. Quantitative histological analysis in the chronic phase of SCI. (A): lesion size was quantified 
on spinal cord longitudinal sections stained with hematoxylin/eosin (Ai) and it was reported as 
cumulative area (mm2). No significant differences among groups were found when measuring both the 
whole cyst area (Aii) and the cavities into the cyst area (Aiii). (B): GAP-43 positive fibers (Bi and Biii, 
red) were measured on six longitudinal sections after immunofluorescence staining and the values were 
expressed as percentage of the total area of the cyst. The GAP-43 immunopositive area was significantly 
higher in biomaterial-treated group (4G-BMHP1) than both control groups (saline and SCI control) (Bii). 
In Biii the positive GAP-43 signal is showed at higher magnification (asterisk and dotted line indicate 
the cyst and its border, respectively). (C): CD68 positive cells (Ci and Ciii, green) were counted on three 
longitudinal sections after immunofluorescence staining and reported as cumulative number per mm2. 
Nuclei were counterstained with DAPI. Macrophage infiltration was observed in the tissue surrounding 
the cyst and into the cavities of all groups (Cii). In Ciii, at higher magnification, an image representative 
of the CD68 positive cells (arrows) was observed in all groups [Adapted from Ref. 30 © PLoS ONE]. 
vicinity of NSPCs. The in vitro differentiation if NSPCs to betaIII-tubulin positive neurons 
was evaluated by immunostaining and mRNA expression. The in vivo studies were 
conducted by transplantation in spinal cord injured rats wherein the survival and 
differentiation of NSPCs was evaluated. For the greatest neuronal differentiation in the 
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presence of constant dbcAMP, the dbcAMP release from PLGA microspheres was optimized 
to release the bioactive for a period of 1 week based on the preliminary in vitro data. As 
depicted in Figure 12, drug release from native microspheres was linear over 11 days while 
the release of dbcAMP occurred over approximately 5 days after incorporation into 
channels. The mass balance results cleared this anomaly in release profiles which showed 
that the there was less drug content in dbcAMP microsphere loaded channels than expected 
microsphere quantity which was further due to drug losses during the process of 
embedding microspheres into the channel. Two major results were reported for the NSPC 
survival and differentiation as follows: 
a. NSPC survival was highest in the dbcAMP pre-treated group, having approximately 
80% survival at both time points as compared to that of stem cell transplantation results 
of less than 1% survival at similar times. 
b. The dbcAMP pre-treatment resulted in the greatest number of in vivo NSPCs 
differentiated into neurons (3764%), followed by dbcAMP-microsphere treated NSPCs 
(27614%) and untreated NSPCs (1567%).  
c. The reverse trend was observed for NSPC-derived oligodendrocytes and astrocytes, 
with these populations being highest in untreated NSPCs. 
d. Chitosan channels implanted in a fully transected spinal cord resulted in extensive 
axonal regeneration into the injury site, with improved functional recovery after 6 
weeks in animals implanted with pre-differentiated stem cells in chitosan channels 
[31]. 
 
Figure 12. Microsphere-loaded channels effectively release dbcAMP in vitro. A) Cumulative release 
profiles of dbcAMP from free-floating microspheres and microsphere-loaded channels. The process of 
embedding microspheres into channel walls is likely responsible for early degradation of PLGA and 
faster drug release from channels. B) Schematic of the entubulation strategy. NSPCs are seeded on fibrin 
scaffold within a chitosan channel. Drug-loaded PLGA microspheres release the differentiation factor 
dibutyryl cyclic-AMP in a local and sustained manner, influencing NSPCs to preferentially differentiate 
into neurons [Adapted from Ref. 31 © PLoS ONE]. 
2.20. Local gene delivery from ECM-coated poly(lactide-co-glycolide) multiple 
channel bridges 
In order to promote transgene expression in the injured spinal cord, Laporte et al., 2009, 
investigated the potential of surface immobilization to deliver complexed DNA (lipoplexes) 
from a multiple channel bridge in order to address the barriers related to cell survival, scar 
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tissue formation, and axonal elongation and guidance by targeting a range of cellular 
processes. The report was based on the inherent low expression levels of lipoplexes due to 
the lipoplex instability upon injection in vivo. The authors postulated that the “local 
delivery of lipoplexes from a biomaterial may have the ability to maintain lipoplex stability, 
and therefore increase the number of transfected cells and transgene expression”. Based on 
their previous study, multiple linear guidance channels were able to support cell infiltration 
and integrate effectively into the spinal cord wherein the channels induced cell orientation 
along its major axis and supported and directed axon elongation across the channels [32]. 
Strategically, lipoplexes were immobilized to the surface of the bridges as follows: 
i. incubation of DNA with extra cellular matrix (ECM)-coated PLGA surfaces 
(incubation), 
ii. drying of ECM onto PLGA and then drying of DNA onto ECM (2-step drying), and  
iii. drying a mixture of DNA and ECM proteins onto PLGA surfaces (1-step drying).  
A series of in vitro studies were carried out to investigate the surface properties of the 
polymer, three ECM proteins (collagen, laminin, and fibronectin), and the immobilization 
strategies for their ability to bind and stabilize the vector, and to transfect cells. In vivo 
studies were performed with a rat spinal cord lateral hemisection model using conditions 
identified from in vitro studies. In conclusion, the combination of the multiple channel 
bridge and gene delivery provided the required physical and chemical guidance cues for 
spinal cord regeneration [33].  
3. Conclusion 
The current drug delivery and tissue engineering techniques discussed in this chapter 
demonstrate that a only a combinatorial approach can provide the desired characteristics 
required for an efficient repair, regeneration, restoration, reconstruction, and reorganisation 
of the neural tissue after traumatic CNS injuries. A synergistic therapeutic approach can be 
designed by incorporating scaffolds with directional cues, bioactives to promote 
regeneration and repair, neural/progenitor cells for release of growth factors, and 
functionalized polymers for better neurocompatibility. Most importantly, the design of 
polymers capable of releasing the drugs, cells and biofactors at a predetermined and 
controlled rate is essential for the success of these tissue engineering approaches (Table 4). 
The chapter provides a comprehensive account of recent as well as long established 
approaches for the delivery of bioactive of neural interest. For further reading, the readers 
are encouraged to read various enlightening reviews in this area as tabulated in Table 5. 
 
S. No. Architecture Biomaterials employed Bioactive incorporated Reference 
1. Injectable gel Hyaluronic Acid-Methyl 
cellulose (blend) 
Nimodipine; 
Erythropoietin  
2-4 
2. Nanoparticles-
incorporated multiple 
channel bridges 
PLGA (scaffold); 
Hydroxyapatite 
(nanoparticles) 
lentiviral vectors 
encoding NT-3 and 
BDNF 
5 
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S. No. Architecture Biomaterials employed Bioactive incorporated Reference 
3. Lipid microtubules- 
incorporated In situ 
gelling hydrogels 
1,2-bis-(triscosa-10,12-
diynoyl)-sn-glycero-3-
phosphocholine;  
Agarose 
brain derived 
neurotrophic factor 
(BDNF) 
6 
4. Photocrosslinked 3D 
scaffold 
Agarose;  
Sulfosuccinimidyl-6- 
[4’-azido-2’-
nitrophenylamino] 
hexanoate 
Laminin-1 7 
5. Nanoparticles-
incorporated injectable 
gel 
PLGA (nanoparticles); 
agarose gel 
Methylprednisolone 9,10 
6. hydrogel-microtube 
delivery system 
Agarose; 1,2-bis-(tricosa-
10,12-diynoyl)-sn-glycero-3-
phosphocholine microtube 
Chondroitinase ABC; 
Rho GTPase, CA-Rac1 
and CA-Cdc42; and 
BDNF 
11,12 
7. 3D Scaffolds PLGA Schwann cells 13 
8. micro-cylinders 
embedded hydrogels 
1,2-bis(10,12-
tricosadiynoyl)-sn-glycero-
3-phosphocholine;  
Agarose 
nerve growth factor 
(NGF) 
14 
9. injectable scaffold Agarose; methylcellulose - 15 
10. Injectable hydrogel acrylated poly(lactic acid)-
b–poly(ethylene glycol)-b–
(poly lactic acid) 
NT-3 16 
11. crosslinked hydrogels 
containing embedded 
microspheres 
hyaluronic acid (HA); 
poly(lactic-co-glycolic acid) 
(PLGA) 
BDNF and VEGF-loaded 17 
12. scaffolds Fibrin; heparin; bi-domain 
peptide (ATIII peptide) 
neurotrophin-3 (NT-3)  20 
13. Nerve guidance channels 
combined with 
microspheres 
poly(hydroxylethylmethacr
ylate-co-
methylmethacrylate); PLGA
Nerve growth factor 24 
14. nanofiber scaffold Self assembling peptides RhoA inhibitor 25 
15. Injectable hydrogel Agarose; carbomer Chondroitinase ABC 
(chABC) 
29 
16. Self assembling peptide 
gel 
RADA16-1  bone marrow homing 
motif (BMHP1) 
30 
17. microspheres embedded 
within guidance 
channels 
poly(lactic-co-glycolic acid) 
(PLGA); Chitosan; fibrin 
dibutyryl cyclic-AMP 
(dbcAMP) 
31 
18. disks and multiple 
channel bridges 
poly(lactic-co-glycolic acid) 
(PLGA) 
DNA complexes 33 
Table 4. Summary of various bioactive-loaded platforms for spinal cord injury intervention 
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S. No. View point discussed in the review Reference 
1. The current approaches to drug delivery from scaffolds for neural tissue 
engineering applications and the challenges presented by attempting to 
replicate the brain, spinal cord, and peripheral nerve tissues were summarized 
34 
2. The complex processes of cell guidance occurring within native ECM; 
strategies to design biomimetic scaffolds able to recapitulate these processes; 
approaches in controlling the release of the relevant factors; challenges to 
design novel scaffolds; time and space orchestrated exposure of 
biomacromolecular moieties 
35 
3. Tissue engineering and novel therapeutic approaches to axonal regeneration 
following spinal cord injury. Axonal growth is supported by inherent 
properties of the selected polymer, the architecture of the scaffold, permissive 
microstructures such as pores, grooves or polymer fibres, and surface 
modifications to provide improved adherence and growth directionality. 
36 
4. The state of the art work in electrospinning and its uses in tissue engineering 
and drug delivery 
37 
5. Electrospun fibers mimic the nanoscale properties of native extracellular 
matrix; the fiber morphology is affected by changing the process parameters 
38 
6. Tissue-engineered implant is a biologic-biomaterial combination in which some 
component of tissue has been combined with a biomaterial to create a device for 
the restoration or modification of tissue or organ function; Specific growth 
factors, released from a delivery device or from co-transplanted cells aid in the 
induction of host paraenchymal cell infiltration and improve engraftment of co-
delivered cells for more efficient tissue regeneration; polymeric device 
development (micropaticles, scaffolds, and encapsulated cells) for therapeutic 
growth factor delivery in the context of tissue engineering was outlined. 
39 
7. The tissue engineering paradigm includes a matrix or scaffold to facilitate 
tissue growth and provide structural support, cells, and the delivery of 
bioactive molecules; injectable materials are designed using processing 
techniques inherent to both tissue engineering and drug delivery. 
40 
8. Basic technology of controlled protein delivery using polymeric materials; 
techniques under investigation for the efficient administration of proteins in 
tissue engineering 
41 
9. An overview of strategies using natural and artificial substrates to present 
active biomolecules in the development of vascular structures; the replacement 
and augmentation of arteries using vascular grafts or stents; the recruitment of 
microvasculature secondary to an ischemic event or for the purpose of 
developing perfused, large volume tissue-engineered constructs 
42 
10. Polyblend nanofibers and nanostructures can act as proxies of the native 
tissue, while providing topographical and biochemical cues that promote 
healing; they are prepared with mixtures of synthetically and naturally 
derived polymers that can behave cooperatively to demonstrate unique 
combinations of mechanical, biochemical and structural properties. 
43 
11. Synthetic polymers used for tissue growth scaffold fabrication and their 
applications in both cell and extracellular matrix support and controlling the 
release of cell growth and differentiation supporting drugs. 
44 
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S. No. View point discussed in the review Reference 
12. In the future, engineered tissues could reduce the need for organ replacement, 
and could greatly accelerate the development of new drugs that may cure 
patients, eliminating the need for organ transplants altogether. 
45 
13. Biodegradable and biocompatible scaffolds have a highly open porous 
structure and good mechanical strength to provide an optimal 
microenvironment for cell proliferation, migration, and differentiation, and 
guidance for cellular in-growth from host tissue; natural and synthetic 
polymeric scaffolds can be fabricated in the form of a solid foam, 
nanofibrous matrix, microsphere, or hydrogel; scaffolds can be surface 
engineered to provide an extracellular matrix mimicking environment for 
better cell adhesion and tissue in-growth and can be designed to release 
bioactive molecules, such as growth factors, DNA, or drugs, in a sustained 
manner 
46 
14. To develop electrospun nanofibers as useful nanobiomaterials, surfaces of 
electrospun nanofibers can be chemically functionalized by plasma treatment, 
wet chemical method, surface graft polymerization, and co-electrospinning of 
surface active agents and polymers for achieving sustained delivery through 
physical adsorption of diverse bioactive molecules such as anti-cancer drugs, 
enzymes, cytokines, and polysaccharides; surfaces can be chemically modified 
with immobilizing cell specific bioactive ligands to enhance cell adhesion, 
proliferation, and differentiation by mimicking morphology and biological 
functions of ECM. 
47 
15. Biomaterials can enable and augment the targeted delivery of drugs or 
therapeutic proteins to the brain, allow cell or tissue transplants to be 
effectively delivered to the brain; help to rebuild damaged circuits; promote 
regeneration; repair damaged neuronal pathways in combination with stem 
cell therapies; nanotechnology allows greater control over material–cell 
interactions that induce specific developmental processes and cellular 
responses including differentiation, migration and outgrowth 
48 
16. Application of biomaterials in (i) shunting systems for hydrocephalus, (ii) 
cortical neural prosthetics, (iii) drug delivery in the CNS, (iv) hydrogel 
scaffolds for CNS repair, and (v) neural stem cell encapsulation for 
neurotrauma 
49 
17. Recent in vivo studies for the regeneration of injured spinal cord, including 
stem-cell transplantation, application of neurotrophic factors and suppressor 
of inhibiting factors, development of biomaterial scaffolds and delivery 
systems, rehabilitation, and the combinations of these therapies 
50 
18. Applications of polymer-based delivery of small molecule drugs, proteins, and 
DNA specifically relevant to neuroscience research; the fabrication procedures 
for the polymeric systems and their utility in various experimental models; 
unique experimental tools with downstream clinical application for the study 
and treatment of neurologic disease offered by biomaterials 
51 
19. Approaches adopted for management of SCI including pharmacologic and gene 
therapy, cell therapy, and use of different cell-free or cell-seeded bioscaffolds; 
developments for therapeutic delivery of stem and nonstem cells to the site of 
injury; application of cell-free/cell-seeded natural and synthetic scaffolds 
52 
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S. No. View point discussed in the review Reference 
20. bioengineered strategies for spinal cord repair using tissue engineered 
scaffolds and drug delivery systems; degradable and non-degradable 
biomaterials; device design; combination strategies with scaffolds. 
53 
21. The merger between the two powerful disciplines—biomaterials engineering 
and stem cell biology 
54 
22. Inclusive survey of biopolymers seeded with Schwann cells (SCs) to be used 
for axonal regeneration in the nervous system 
55 
23. Recent studies that utilize electrospun nanofibers to manipulate biological 
processes relevant to nervous tissue regeneration, including stem cell 
differentiation, guidance of neurite extension, and peripheral nerve injury 
treatments 
56 
24. Smart biomaterials are capable to carry and deliver cells and/or drugs in the 
damaged spinal cord; an overview of a wide range of natural, synthetic, and 
composite hydrogels 
57 
25. Self-assembled materials provide the ability to tailor specific bulk material 
properties, such as release profiles, at the molecular level via monomer design; 
an overview of self-assembling molecules, their resultant structures, and their 
use in therapeutic delivery; current progress in the design of polymer- and 
peptide-based self-assembled materials. 
58 
Table 5. Leading review reports incorporating the inherent mechanistic and fabrication details of 
various neural architectures employed for neural tissue engineering and drug delivery 
Author details 
Viness Pillay*, Pradeep Kumar, Yahya E. Choonara and Lisa C. du Toit 
University of the Witwatersrand, Faculty of Health Sciences,  
Department of Pharmacy and Pharmacology, Parktown, Johannesburg, South Africa 
Girish Modi 
University of the Witwatersrand, Faculty of Health Sciences, Division of Neurosciences,  
Department of Neurology, Parktown, Johannesburg, South Africa 
Dinesh Naidoo 
University of the Witwatersrand, Faculty of Health Sciences, Division of Neurosciences,  
Department of Neurosurgery, Parktown, Johannesburg, South Africa 
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